Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Gross Margin (2020 - 2025)

BridgeBio Pharma's Gross Margin history spans 6 years, with the latest figure at 94.74% for Q4 2025.

  • On a quarterly basis, Gross Margin rose 3017.0% to 94.74% in Q4 2025 year-over-year; TTM through Dec 2025 was 95.82%, a 243.0% decrease, with the full-year FY2025 number at 95.82%, down 243.0% from a year prior.
  • Gross Margin hit 94.74% in Q4 2025 for BridgeBio Pharma, roughly flat from 94.56% in the prior quarter.
  • Over the last five years, Gross Margin for BBIO hit a ceiling of 99.72% in Q1 2024 and a floor of 118.64% in Q3 2022.
  • Historically, Gross Margin has averaged 69.14% across 5 years, with a median of 81.3% in 2021.
  • Biggest five-year swings in Gross Margin: crashed -15661bps in 2022 and later surged 20402bps in 2023.
  • Tracing BBIO's Gross Margin over 5 years: stood at 84.49% in 2021, then decreased by -23bps to 65.4% in 2022, then rose by 1bps to 65.73% in 2023, then decreased by -2bps to 64.57% in 2024, then surged by 47bps to 94.74% in 2025.
  • Business Quant data shows Gross Margin for BBIO at 94.74% in Q4 2025, 94.56% in Q3 2025, and 96.7% in Q2 2025.